Market Herald logo

Subscribe

Be the first with the news that moves the market
  • NeuroScientific Biopharmaceuticals (NSB) has received ethics approval for an early-phase clinical trial of EmtinB
  • The Human Research Ethics Committee (HREC) confirmed the trial could be undertaken in up to 30 health volunteers
  • EmtinB aims to reduce inflammatory growth proteins (cytokines), which are linked to a number of diseases
  • The trial will focus on assessing biomarkers in human blood to prove the success of the drug so it can be used to guide efficacy outcomes in future trials
  • Shares were trading 10.9 per cent higher today at 25.5 cents each at 11:46 am AEST

NeuroScientific Biopharmaceuticals (NSB) has received ethics approval for an early phase clinical trial of EmtinB.

The Human Research Ethics Committee (HREC) confirmed the trial could be undertaken in up to 30 health volunteers.

EmtinB aims to reduce inflammatory growth proteins (cytokines) which are linked to a number of diseases, including Alzheimer’s and glaucoma.

The trial will focus on assessing biomarkers in human blood to prove the success of the drug so it can be used to guide efficacy outcomes in future trials.

The company expects to start recruiting subjects immediately.

Managing Director and CEO Matt Liddelow said this is a milestone moment in progressing the drug towards commercialisation.

“This clinical trial forms the initial part of our clinical development strategy for EmtinB as a potential disease modifying treatment for neurodegenerative conditions, such as our lead indications Alzheimer’s disease and multiple sclerosis,” he said.

Shares were trading 10.9 per cent higher today at 25.5 cents each at 11:46 am AEST.

NSB by the numbers
More From The Market Herald
Cavalier Resources (ASX:CVR) - Executive Technical Director, Daniel Tuffin

" Cavalier Resources (ASX:CVR) begins PFS at Crawford

Cavalier Resources (ASX:CVR) has begun a pre-feasibility study (PFS) at the Crawford Gold Project within the…
Ten Sixty Four (ASX:X64) - Outgoing Managing Director, Paul Ryan Welker

" Ten Sixty Four (ASX:X64) terminates services agreement of former MD, Paul Ryan Welker

Ten Sixty Four (ASX:X64) has terminated the executive services agreement of former Managing Director Paul Ryan…

" M3 Mining (ASX:M3M) identifies drill targets at Edjudina

M3 Mining (ASX:M3M) has identified prospective gold-in-soil anomalies at the Edjudina gold project 150 kilometres northeast…

" Good Drinks Australia (ASX:GDA) commences the sale of Molson Coors and Magners

Good Drinks Australia (ASX:GDA) begins to sell the Miller Chill, Miller Genuine Draught, Coors, Molson Canadian…